China Medical System Holdings Limited (CMS) has marked its successful secondary listing on the Singapore Exchange (SGX) by hosting a high-profile forum in Singapore. The event, held on 15 July 2025 at CMS’s PharmaGend facility in Tuas, highlighted the company’s strategy to use Singapore as a regional hub to drive pharmaceutical innovation and expansion across emerging markets.
The forum attracted around 150 representatives from various sectors, including government agencies, pharmaceutical companies, and investment institutions. Discussions centred on the development of the pharmaceutical industry in Singapore and emerging markets, as well as the expansion of Chinese innovative drugs globally.
SGX’s Caihan Chia noted that CMS’s listing underscores the growing interest of Chinese companies in Singapore, driven by policy refinements and capital support. This move is expected to enhance CMS’s ability to connect with international investors and reinforce Singapore’s role as a capital hub.
Emerging markets such as Southeast Asia and the Middle East are becoming significant growth drivers for the pharmaceutical industry, with demand for medicines rising due to factors like ageing populations and increased health awareness. CMS aims to tap into these markets by building a dual hub strategy in China and Singapore, focusing on end-to-end innovation.
CMS Chairman Lam Kong outlined the company’s transformation strategy, which includes product innovation, commercial transformation, and international expansion. The company has developed a pipeline of nearly 40 innovative drugs and is expanding its presence in emerging markets through strategic partnerships and localised manufacturing capabilities.
With its strategic initiatives, CMS is poised to enhance its global value chain and unlock growth opportunities in emerging markets, setting a new paradigm for Chinese pharmaceutical companies expanding overseas.
“`
